ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatmentChildren ages ...
Credit: Arcutis. Zoryve topical foam is a once-daily steroid-free formulation of a highly potent and selective phosphodiesterase type 4 inhibitor. The Food and Drug Administration (FDA) has approved ...
Credit: Arcutis. The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis ...
Once-daily ZORYVE foam provides powerful clearance and rapid itch relief from head to toe with no limitation on duration of use More than half of the nearly 9 million people in the United States with ...
Arcutis Biotherapeutics (NASDAQ:ARQT) executives highlighted strong recent commercial performance for ZORYVE and outlined near-term regulatory and pipeline milestones during a presentation and ...
About a year after Arcutis Biotherapeutics unveiled positive data on roflumilast foam at the European Academy of Dermatology and Venereology congress 2022, the company has clinched a second FDA OK.
Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on developing innovations in immuno-dermatology, announced the U.S. Food and Drug Administration has approved the ...
Arcutis Biotherapeutics is going straight to consumers to let them know that Zoryve is The Cream That Can. On Tuesday morning, the early commercial-stage biopharmaceutical company launched its first ...
ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...
While "seborrheic dermatitis" (seb derm) may not be a household name, one of its most common visible symptoms—flakes that may ...
ZORYVE ® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, ...
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results